A study [23], which examined 29 refractory DME patients that received combined high-dose sub-tenon triamcinolone, laser photocoagulation, and anti-VEGF injections, found a postinjection ptosis rate of 17.2%, with a mean time of onset of 6 months (range 3–9 months). The gene discussed is VEGFA; the disease is ptosis.